GO:1901186 positive regulation of ERBB signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901186 describes any process that activates or increases the frequency, rate or extent of ERBB signaling pathway.
• ERBB signaling is initiated by ligand-induced dimerization of EGFR/ERBB1, ERBB2, ERBB3 and ERBB4, followed by trans-autophosphorylation and recruitment of adaptor proteins.
• Positive regulation of ERBB signaling is frequently hijacked in cancer through receptor overexpression, activating mutations, autocrine ligand loops and loss of negative feedback.
• Cancer-associated fibroblasts can sustain EGFR signaling via the CTHRC1/glycolysis/H3K18la positive feedback loop, contributing to EGFR-TKI resistance.
• IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect causal regulators of ERBB signaling.
Description
The Gene Ontology term GO:1901186, positive regulation of ERBB signaling pathway, is a biological process that encompasses any molecular event that activates or increases the frequency, rate or extent of signaling through the ERBB family of receptor tyrosine kinases. The ERBB family comprises EGFR (ERBB1), ERBB2 (HER2), ERBB3 and ERBB4, which transduce extracellular growth factor signals into intracellular cascades controlling proliferation, survival, migration and differentiation. Because dysregulated ERBB signaling is a hallmark of many epithelial cancers, understanding its positive regulation is central to both basic signal transduction research and therapeutic development. Mechanistically, positive regulation can occur at multiple levels: increased ligand availability, receptor overexpression, enhanced dimerization, impaired negative feedback, or cross-talk with other signaling modules. For example, in non-small cell lung cancer, EGFR transcriptionally upregulates UTX via STAT3, illustrating how ERBB signaling can feed forward to epigenetic regulators. In glioblastoma, CEBPD acts as a master transcriptional factor for hypoxia-regulated proteins and augments hypoxia-induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway activation. Such examples highlight that positive regulation of ERBB signaling is not a single linear event but a network of interconnected positive feedback loops [1,3,4]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:1901186, covering its definition, core mechanisms, key genes, disease relevance, and experimental strategies including CRISPR-based models. All factual statements are supported by the cited literature [1-8].
positive regulation of ERBB signaling pathway At A Glance
| GO ID | GO:1901186 |
|---|---|
| GO term | positive regulation of ERBB signaling pathway |
| Ontology | biological_process |
| Synonym | activation of ERBB signaling pathway; upregulation of EGFR family signaling pathway; positive regulation of ErbB signaling |
| Major function | Increases the frequency, rate or extent of ERBB receptor tyrosine kinase signaling |
| Related receptors | EGFR (ERBB1), ERBB2 (HER2), ERBB3, ERBB4 |
| Key downstream pathways | MAPK/ERK, PI3K/AKT, STAT3 [3,5] |
| Disease relevance | Non-small cell lung cancer, glioblastoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma [1,2,3,4,6,8] |
What Is GO:1901186?
GO:1901186 is defined by QuickGO as any process that activates or increases the frequency, rate or extent of ERBB signaling pathway. In practical terms, it includes molecular events that enhance ligand binding, receptor dimerization, kinase activity, adaptor recruitment, downstream MAPK/PI3K-AKT activation, or that suppress negative regulators of ERBB signaling.
Why Is positive regulation of ERBB signaling pathway Important in Cell Biology?
Positive regulation of ERBB signaling is critically important because excessive or sustained ERBB activity drives tumor initiation, progression, metastasis and resistance to targeted therapies. In non-small cell lung cancer, EGFR mutations and bypass signaling through MET or AKT can confer resistance to osimertinib. In pancreatic ductal adenocarcinoma, reciprocal regulation of MMP-28 and EGFR sustains proliferative signaling. In hepatocellular carcinoma, RAB40C recruits TRIM21 to stabilize EGFR and facilitate progression. Understanding the positive regulators of ERBB signaling therefore informs biomarker discovery, drug resistance mechanisms and combination therapeutic strategies [1,2,5,6,8].
• ERBB receptors are among the most frequently dysregulated oncoproteins in human cancers.
• Positive regulation of ERBB signaling contributes to resistance to EGFR-targeted therapies such as osimertinib.
• Cancer-associated fibroblasts can promote EGFR-TKI resistance via metabolic-epigenetic feedback loops.
• Hypoxia-induced CEBPD enhances EGFR/PI3K pathway activation and invasion in glioblastoma.
• EGFR signaling can transcriptionally upregulate epigenetic regulators such as UTX via STAT3.
• MMP-28 and EGFR form a reciprocal regulatory loop that sustains proliferative signaling in PDAC.
• RAB40C-mediated stabilization of EGFR promotes hepatocellular carcinoma progression.
• Adaptor proteins such as SEM-5/GRB2 modulate positive versus negative signaling of LET-23/EGFR.
• CRISPR screens can identify novel positive regulators of ERBB signaling for therapeutic targeting.
• Modeling positive regulation in cell systems enables functional validation of candidate genes.
What Happens During positive regulation of ERBB signaling pathway?
Ligand availability and receptor activation
In simple terms: More ligand or more receptor means stronger signal.
Positive regulation can begin with increased availability of EGF-family ligands or overexpression of ERBB receptors at the cell surface. Ligand binding induces receptor dimerization and trans-autophosphorylation, creating docking sites for adaptor proteins such as GRB2 and SHC. In C. elegans, the adaptor protein SEM-5 (ortholog of GRB2) modulates positive versus negative signaling downstream of LET-23/EGFR, demonstrating that adaptor abundance and availability are critical determinants of signal strength.
Receptor stabilization and trafficking
In simple terms: Keeping the receptor around longer boosts signaling.
Positive regulation of ERBB signaling can occur through mechanisms that stabilize the receptor and prevent its degradation. RAB40C recruits TRIM21 to stabilize EGFR, facilitating hepatocellular carcinoma progression. This illustrates that ubiquitin-proteasome and endosomal trafficking pathways are key nodes where positive regulation is exerted. Similarly, IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer, showing that bypass receptor stabilization can sustain downstream signaling.
Transcriptional and epigenetic feedback
In simple terms: Signaling can turn on genes that make the signal even stronger.
ERBB signaling can initiate transcriptional programs that reinforce the pathway itself [3,4]. EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer, linking receptor activity to epigenetic regulation. In glioblastoma, CEBPD acts as a master transcriptional factor for hypoxia-regulated proteins and augments hypoxia-induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway activation. These examples show that positive regulation often involves feed-forward transcriptional loops [3,4].
Metabolic-epigenetic positive feedback
In simple terms: Metabolism and gene expression can lock in high ERBB signaling.
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop. This demonstrates that positive regulation of ERBB signaling can be embedded within metabolic and epigenetic circuits, where lactate production and histone lactylation reinforce receptor signaling and drug resistance. Such feedback loops represent attractive targets for combination therapy.
Cross-talk with other receptor systems
In simple terms: Other receptors can amplify ERBB signals.
Positive regulation of ERBB signaling frequently involves cross-talk with other receptor tyrosine kinases and signaling modules [2,6]. In PDAC, reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling. In EGFR-mutant NSCLC, IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation. These examples highlight that positive regulation is often mediated by parallel or downstream pathways that converge on ERBB effectors [2,6].
Key Genes Involved in GO:1901186 positive regulation of ERBB signaling pathway
The following genes and proteins are central to positive regulation of ERBB signaling, based on verified literature and canonical pathway knowledge.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR (ERBB1) | Receptor tyrosine kinase that initiates ERBB signaling upon ligand binding | Most frequently mutated/overexpressed oncogene in NSCLC and other cancers |
| ERBB2 (HER2) | Co-receptor that enhances dimerization and signaling potency | Target of trastuzumab and other therapies in breast and gastric cancer |
| ERBB3 | Kinase-dead receptor that partners with ERBB2 to activate PI3K/AKT | Important in PI3K-driven cancers and resistance |
| ERBB4 | Receptor with tissue-specific roles in development and cancer | Less studied but relevant in neuronal and breast biology |
| STAT3 | Transcription factor downstream of EGFR that upregulates UTX | Mediates transcriptional feedback and epigenetic regulation |
| UTX (KDM6A) | Histone demethylase upregulated by EGFR-STAT3 signaling | Links ERBB signaling to chromatin remodeling in NSCLC |
| CEBPD | Transcription factor induced by hypoxia that augments EGFR/PI3K pathway | Promotes invasion in glioblastoma |
| CTHRC1 | Secreted protein from CAFs that promotes glycolysis and H3K18la | Drives EGFR-TKI resistance via metabolic-epigenetic loop |
| IFITM3 | Interferon-induced transmembrane protein that interacts with MET | Drives osimertinib resistance through AKT activation |
| MET | Receptor tyrosine kinase that bypasses EGFR inhibition | Mediates resistance to EGFR-TKIs in NSCLC |
| MMP-28 | Matrix metalloproteinase reciprocally regulated with EGFR | Sustains proliferative signaling in PDAC |
| RAB40C | Small GTPase that recruits TRIM21 to stabilize EGFR | Promotes hepatocellular carcinoma progression |
| TRIM21 | E3 ubiquitin ligase that stabilizes EGFR when recruited by RAB40C | Modulates EGFR turnover in HCC |
| GRB2/SEM-5 | Adaptor protein that couples activated EGFR to RAS-MAPK | Modulates positive versus negative signaling |
| PIK3CA | Catalytic subunit of PI3K downstream of ERBB receptors | Frequently mutated in cancers with ERBB activation |
| AKT1 | Serine/threonine kinase downstream of PI3K | Mediates survival signaling and drug resistance |
| MAPK1/ERK2 | Terminal kinase of the MAPK cascade downstream of ERBB | Drives proliferation and is a key effector of ERBB signaling |
How Is positive regulation of ERBB signaling pathway Regulated?
Positive regulation of ERBB signaling is itself tightly regulated by multiple mechanisms. Negative feedback loops involving receptor internalization, ubiquitination and dephosphorylation normally constrain signal duration and intensity. Adaptor proteins such as SEM-5/GRB2 can shift the balance between positive and negative signaling outcomes. In cancer, these regulatory mechanisms are frequently disrupted, leading to sustained ERBB activation. For example, RAB40C-mediated stabilization of EGFR bypasses normal degradation pathways, while IFITM3-MET interaction provides a bypass route that maintains AKT activation even under EGFR inhibition. Metabolic and epigenetic feedback loops, such as the CTHRC1/glycolysis/H3K18la circuit, further reinforce positive regulation and contribute to therapy resistance.
positive regulation of ERBB signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Non-small cell lung cancer; EGFR-TKI resistance [2,3] | EGFR-mutant NSCLC cell lines with CRISPR knockout of resistance genes |
| CTHRC1 | Cancer-associated fibroblast-driven EGFR-TKI resistance | Co-culture models of CAFs and NSCLC cells with CTHRC1 knockout |
| IFITM3 | Osimertinib resistance in EGFR-mutant NSCLC | IFITM3 knockout or overexpression in osimertinib-resistant cells |
| CEBPD | Glioblastoma hypoxia-induced invasion | Glioblastoma cell lines under hypoxia with CEBPD knockout |
| RAB40C | Hepatocellular carcinoma progression | HCC cell lines with RAB40C knockout or overexpression |
Non-small cell lung cancer and EGFR-TKI resistance
Positive regulation of ERBB signaling is central to NSCLC pathogenesis and resistance to EGFR tyrosine kinase inhibitors [2,3]. EGFR transcriptionally upregulates UTX via STAT3, linking receptor activity to epigenetic reprogramming. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation, providing a mechanism of bypass signaling. Cancer-associated fibroblasts can also promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop. These findings underscore the clinical importance of identifying and targeting positive regulators of ERBB signaling [1,2,3].
Glioblastoma and hypoxia-driven invasion
In glioblastoma, CEBPD acts as a master transcriptional factor for hypoxia-regulated proteins and augments hypoxia-induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway activation. This illustrates how the tumor microenvironment can positively regulate ERBB signaling to promote aggressive phenotypes.
Pancreatic ductal adenocarcinoma and proliferative signaling
Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. This bidirectional positive feedback loop highlights the complexity of ERBB regulation in gastrointestinal cancers.
Hepatocellular carcinoma and receptor stabilization
RAB40C recruits TRIM21 to stabilize EGFR, facilitating the progression of hepatocellular carcinoma. This mechanism represents a distinct mode of positive regulation through inhibition of receptor degradation.
From positive regulation of ERBB signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for ERBB signaling? | CRISPR knockout in ERBB-dependent cancer cell lines |
| Does a specific mutation activate ERBB signaling? | CRISPR point-mutation knock-in of the mutation in endogenous locus |
| Does a tag affect receptor trafficking? | CRISPR knock-in of fluorescent or affinity tag on ERBB receptor |
| Does overexpression of a regulator enhance signaling? | CRISPR overexpression or lentiviral overexpression |
| Which genes regulate ERBB signaling in a genome-wide manner? | CRISPR library screening with ERBB pathway reporter |
| Does a candidate gene mediate drug resistance? | CRISPR knockout in resistant cell lines followed by drug sensitivity assay [1,2] |
How to Study the positive regulation of ERBB signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on ERBB signaling | Identify required positive regulators |
| CRISPR point mutation | Effect of specific mutation on pathway activity | Model activating mutations in EGFR or effectors |
| RNA-seq | Transcriptional changes downstream of ERBB | Discover feedback loops and target genes [3,4] |
| ChIP-seq | Chromatin binding by transcription factors | Map STAT3 or CEBPD binding sites [3,4] |
| Co-immunoprecipitation | Protein-protein interactions | Identify complexes stabilizing EGFR |
| Western blot | Phosphorylation status of ERBB effectors | Quantify pathway activation [2,5] |
| CRISPR library screen | Genome-wide regulators of ERBB signaling | Unbiased discovery of positive regulators |
| Drug sensitivity assay | Response to EGFR-TKIs | Link positive regulators to resistance [1,2] |
CRISPR knockout and point-mutation models
CRISPR-Cas9 knockout is widely used to test whether a candidate gene is required for positive regulation of ERBB signaling. Point-mutation knock-in can model activating mutations in EGFR or downstream effectors to study their impact on pathway activity. These approaches enable causal inference beyond correlative observations.
Transcriptomic and epigenomic profiling
RNA-seq and ChIP-seq can reveal transcriptional and epigenetic feedback loops downstream of ERBB activation [3,4]. For example, EGFR-STAT3-mediated upregulation of UTX was identified through such approaches. CEBPD-dependent gene expression under hypoxia was also characterized using transcriptomic methods.
Proteomic and interactomic analyses
Proteomics and co-immunoprecipitation can identify protein complexes that positively regulate ERBB signaling, such as RAB40C-TRIM21-EGFR or IFITM3-MET. These methods are essential for mapping the molecular machinery of positive regulation [2,8].
Functional screens and reporter assays
CRISPR library screening with ERBB pathway reporters can identify novel positive regulators in an unbiased manner. Luciferase-based reporters of MAPK or PI3K activity are commonly used to quantify pathway output.
How CRISPR Can Be Used to Study GO:1901186 positive regulation of ERBB signaling pathway
Knockout
CRISPR knockout of candidate genes is used to determine whether they are necessary for positive regulation of ERBB signaling. For example, knocking out IFITM3 or MET can reverse osimertinib resistance in EGFR-mutant NSCLC models. Similarly, CTHRC1 knockout in cancer-associated fibroblasts can disrupt the glycolysis/H3K18la feedback loop that sustains EGFR signaling.
Point Mutation
CRISPR point-mutation knock-in allows precise modeling of activating or resistance mutations in ERBB pathway components. This approach can be used to introduce mutations in EGFR or downstream effectors to study their impact on pathway activity and drug response.
Knock-in
CRISPR knock-in of tags or reporters enables real-time monitoring of ERBB receptor trafficking, localization and interactions. Tagged knock-in of EGFR or ERBB2 can facilitate imaging and proteomic studies of positive regulation.
Overexpression
CRISPR activation or lentiviral overexpression can be used to test whether increasing the abundance of a candidate gene enhances ERBB signaling. Overexpression of RAB40C, for example, stabilizes EGFR and promotes hepatocellular carcinoma progression.
How EDITGENE Supports positive regulation of ERBB signaling pathway Research
Researchers studying positive regulation of ERBB signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, drug resistance or tumor progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ERBB signaling pathway research.
Frequently Asked Questions About positive regulation of ERBB signaling pathway
What is GO:1901186?
GO:1901186 is the Gene Ontology term for positive regulation of ERBB signaling pathway, defined as any process that activates or increases the frequency, rate or extent of ERBB signaling pathway.
What genes are involved in positive regulation of ERBB signaling pathway?
Key genes include EGFR, ERBB2, ERBB3, ERBB4, STAT3, UTX, CEBPD, CTHRC1, IFITM3, MET, MMP-28, RAB40C, TRIM21, GRB2, PIK3CA, AKT1 and MAPK1 [1-8].
How is ERBB signaling positively regulated in cancer?
Positive regulation occurs through receptor overexpression, activating mutations, autocrine ligand loops, receptor stabilization, bypass signaling and metabolic-epigenetic feedback loops [1,2,5,8].
What is the role of EGFR in ERBB signaling?
EGFR (ERBB1) is a receptor tyrosine kinase that initiates ERBB signaling upon ligand binding and is frequently mutated or overexpressed in cancers.
How does CTHRC1 contribute to EGFR-TKI resistance?
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.
What is the role of IFITM3 in osimertinib resistance?
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.
How does RAB40C regulate EGFR?
RAB40C recruits TRIM21 to stabilize EGFR, facilitating the progression of hepatocellular carcinoma.
What experimental models are used to study positive regulation of ERBB signaling?
CRISPR knockout, point-mutation, knock-in, overexpression models and CRISPR library screening are commonly used.
Why is positive regulation of ERBB signaling important for drug discovery?
It informs mechanisms of resistance to EGFR-targeted therapies and identifies candidate targets for combination therapy [1,2,5].
How can EDITGENE help with ERBB signaling research?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening and bioinformatics services to study positive regulation of ERBB signaling.
Conclusion
GO:1901186, positive regulation of ERBB signaling pathway, represents a complex and clinically important biological process that integrates ligand availability, receptor stabilization, transcriptional feedback, metabolic-epigenetic loops and cross-talk with other signaling pathways [1-8]. Dysregulation of this process is a hallmark of multiple cancers and a major driver of resistance to targeted therapies [1,2,5]. CRISPR-based functional genomics, combined with transcriptomic, proteomic and imaging approaches, provides powerful tools to dissect the causal regulators of ERBB signaling. Continued research into positive regulation of ERBB signaling will likely yield new therapeutic strategies for cancers dependent on this pathway [1-8].
References
- 1. Zhang C et al.. 2025. Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.. Oncogene 44(19):1400-1414 PMID: 40011576
- 2. Ibusuki R et al.. 2025. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.. Mol Cancer 24(1):272 PMID: 41152910
- 3. Zhou L et al.. 2022. EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.. J Cancer Res Clin Oncol 148(2):309-319 PMID: 34661759
- 4. Mao XG et al.. 2023. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.. Cell Death Dis 14(4):269 PMID: 37059730
- 5. Wang Z. 2017. ErbB Receptors and Cancer.. Methods Mol Biol 1652:3-35 PMID: 28791631
- 6. Hong Z et al.. 2025. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC.. J Exp Clin Cancer Res 44(1):68 PMID: 39994761
- 7. Worby C et al.. 2000. Positive versus negative signaling of LET-23: regulation through the adaptor protein, SEM-5.. Sci STKE 2000(63):pe2 PMID: 11752629
- 8. Wang Y et al.. 2025. RAB40C recruiting TRIM21 facilitates the progression of hepatocellular carcinoma by stabilizing EGFR.. Cell Commun Signal 24(1):14 PMID: 41350889
